BioPharma Resources

Drug Trial Radar · NCT02645370

Efficacy and Safety of Danzhen

Efficacy and Safety of Danzhen in the Preventive Treatment of Migraine:A Prospective "Real-World" Study.

Last checked: Nov 19, 2026Latest source record: Jan 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

3,300

Planned (sponsor's estimate)

Start

Feb 2016

Primary completion

Jul 2017

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ecion Pharmaceutical CO..LTD
First posted
Jan 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose is to evaluate the effectiveness and safety profile of Danzhen for the prophylaxis of migraine in a "real-world" setting.

Conditions

  • Migraine

Interventions

  • DanzhenDrug

  • TopiramateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A 50% or greater reduction in headache days/month during the third treatment month of maintenance phase relative to baseline phase with one of the study drugs.Time frame: at baseline phase/the third treatment month of maintenance phase

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xijing Hospital

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.